By Staff
Monday, October 3, 2022 12:30 AM
ATLANTA—
EyeSouth Partners, a comprehensive ophthalmology platform, based here, announced that private equity firm
Olympus Partners has taken a majority stake in the company. Founded in 1988, Olympus is an active, long-term investor across a broad range of industries including business services, consumer products, health care services, financial services, industrial services and manufacturing. Prior to the acquisition, EyeSouth was backed by
Shore Capital Partners, a Chicago-based private equity firm that had managed the company’s growth since its founding in 2017. EyeSouth’s physicians will remain significant investors alongside Olympus and management, the company said.
By Staff
Friday, September 30, 2022 12:24 AM
ATLANTA—
EyeSouth Partners has completed affiliations with Arbor Centers for EyeCare and Chicago Eye Institute, leading ophthalmic practices in Chicagoland for decades, which are supported by the Ocular Partners Management Services Organization.
By Staff
Monday, September 26, 2022 12:18 AM
CHARENTON-LE-PONT, France—
EssilorLuxottica announced the launch of a share buyback program for the purchase of up to 1,500,000 EssilorLuxottica shares, depending on market conditions, over a period starting Sept. 23, 2022, and continuing until March 31, 2023.
By Staff
Tuesday, September 20, 2022 12:33 AM
MURRELLS INLET, S.C.—
Eastern Eye Care, founded by Shawn Thomas, OD, has joined the growing
US Eye network of eyecare practices. The addition of Eastern Eye Care continues US Eye’s expansion throughout coastal South Carolina and adds a presence in the growing Grand Strand area, centered around Myrtle Beach. The expansion follows US Eye’s entry into the Hilton Head area in 2021. Details of the transaction were not disclosed. “Myrtle Beach in particular has been an area of interest for us as we have seen an influx of residents traveling to our Carolina Eyecare Physicians offices for ophthalmic services,” said Dr. Kerry Solomon, chief medical officer of US Eye and Cataract Surgeon at Carolina Eyecare Physicians.
By Staff
Tuesday, September 20, 2022 12:27 AM
BOCA RATON, Fla.—
Premier Eye Care announced the promotion of Duane Carter to the new role of vice president of information management and solutions.
By Staff
Saturday, September 17, 2022 12:21 AM
COLUMBUS, Ga.—
Eye Health America (EHA) has acquired a stake in
West Georgia Eye Care Center, the largest multi-specialty ophthalmic practice in Columbus, Georgia. This is EHA’s second partnership in Georgia, and 22nd overall. Details of the transaction were not disclosed.
By Staff
Tuesday, September 13, 2022 12:36 AM
DALLAS, Texas—Yesterday
Neurolens announced the completion of an additional $67 million in financing. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wace, and existing investors including Bluestem Capital. The investment will fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens, according to an announcement from the company. “While we have grown tenfold in the past three years, the unmet patient need remains massive,” said Pierre Bertrand, Neurolens CEO.
By Staff
Tuesday, September 13, 2022 12:21 AM
ST. LOUIS—Members of the
American Optometric Association looking to improve their financial health will now have access to three new products aimed at doctors of optometry. These three new products from AOAExcel’s long-time business partner Laurel Road include High Yield Savings, Linked Checking, and a Student Loan Cashback credit card.
By Staff
Friday, September 9, 2022 12:24 AM
ATLANTA—
EyeSouth Partners has completed an affiliation with
Raleigh Ophthalmology. The move represents EyeSouth’s 31st affiliation overall and first in the state of North Carolina.
By Staff
Friday, September 2, 2022 12:24 AM
SAN RAMON, Calif.—
CooperCompanies (NYSE: COO) reported strong financial results for its fiscal third quarter ended July 31, 2022. Revenue increased 10 percent (18 percent in constant currency) year-over-year to $843.4 million. CooperVision (CVI) revenue rose 2 percent (10 percent in constant currency) to $566.3 million. CooperSurgical (CSI) revenue climbed 35 percent (39 percent in constant currency), to $277.1 million. The growth was led by the daily silicone hydrogel portfolio in myopia management products for CooperVision and fertility for CooperSurgical, according to CooperCompanies.
By Staff
Tuesday, August 30, 2022 12:24 AM
HAMBURG, Germany—European optical retailer
Fielmann Group (FIE:Vienna), based here, announced last week that it is investing more than €65 million in a new high-tech facility consisting of an eyewear production as well as a highly automated fulfilment center in Chomutov, Czech Republic. The construction is ongoing and operations are scheduled to start in 2024.
By Staff
Friday, August 26, 2022 12:24 AM
LAVAL, Quebec—
Bausch Health Cos. (NYSE/TSX: BHC) said this week that it has transferred common shares in an amount equal to approximately 38.6 percent of the issued and outstanding shares of
Bausch + Lomb Corp. to an existing wholly owned unrestricted subsidiary of Bausch Health. This transfer is consistent with the company's “commitment to the separation of Bausch + Lomb and provides the company with strategic flexibility while it evaluates all relevant factors and considerations relating to the separation of Bausch + Lomb,” the Bausch Health announcement noted.
By Staff
Wednesday, August 24, 2022 12:27 AM
GENEVA & DURHAM, N.C.—
Alcon (SIX/NYSE: ALC) and
Aerie Pharmaceuticals (NASDAQ: AERI), yesterday announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie. The transaction is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial expertise. Through the transaction, Alcon will add the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.